The global preimplantation genetic testing (PGT) market is on a steady upward trajectory, driven by rising infertility rates, growing awareness of genetic disorders, and rapid technological advancements in reproductive medicine. According to recent market projections, the sector is expected to reach a valuation of US$552.7 million in 2025, and further expand to US$999.2 million by 2032, registering a CAGR of 8.8% during the forecast period. With its ability to screen embryos for genetic anomalies prior to implantation, PGT continues to transform assisted reproductive technologies and improve the chances of successful pregnancies.

Rising Demand for Genetic Screening Amid Growing Fertility Challenges

Infertility has become an increasingly prevalent global concern, driven by lifestyle changes, environmental factors, and delayed family planning. As more couples turn to in-vitro fertilization (IVF) and related treatments, demand for preimplantation genetic testing has surged. PGT enables clinicians to identify chromosomal abnormalities, single-gene disorders, and hereditary conditions before embryo transfer, significantly improving IVF outcomes and reducing risks of miscarriage or inherited disease transmission.

From 2019 to 2024, the market witnessed consistent expansion, supported by enhanced accessibility to fertility services, a broader acceptance of genetic screening, and rapid innovations in next-generation sequencing (NGS) technologies. As the world enters the next stage of reproductive genomics, PGT is set to become a routine part of fertility treatment protocols across developed and emerging economies.

Market Segmentation Analysis

By Product

The preimplantation genetic testing market includes kits, and reagents and consumables, with the latter segment accounting for the majority of market revenue. Consumables are widely used in repeated testing cycles, driving consistent demand across laboratories and fertility clinics. As testing volumes rise globally, manufacturers are focusing on developing more accurate, high-throughput, and cost-effective consumables that ensure precise genetic analysis with minimal sample requirements.

By Technology

Several advanced technologies are employed in PGT, each offering unique advantages depending on clinical requirements.

Next-Generation Sequencing (NGS)
NGS stands as the leading technology, offering unparalleled accuracy in detecting chromosomal abnormalities, single-gene mutations, and structural variants. Its ability to sequence multiple DNA fragments simultaneously has made it the gold standard for modern genetic testing.

Fluorescence In Situ Hybridization (FISH)
Although traditionally one of the earliest technologies in PGT, FISH continues to be used for targeted chromosomal analysis, particularly in settings where cost and accessibility remain concerns.

Polymerase Chain Reaction (PCR)
PCR plays a crucial role in amplifying DNA sequences to detect single-gene disorders. Its precision and reliability have made it indispensable for identifying hereditary mutations.

Single-Nucleotide Polymorphism (SNP)
SNP genotyping enables comprehensive examination of genetic variations and assists in identifying monogenic diseases and chromosomal translocations.

Comparative Genomic Hybridization (CGH)
CGH allows genome-wide screening for aneuploidies and remains a vital tool for detecting copy number variations in embryos.

Together, these technologies are driving the evolution of embryo diagnosis, empowering clinicians with deeper genomic insights and improving decision-making in fertility treatments.

By Application

The PGT market spans multiple critical applications:

Aneuploidy Screening
Aneuploidy remains the most common cause of failed IVF cycles and miscarriages. PGT-A testing has become widely adopted to ensure chromosomally normal embryos are selected, increasing pregnancy success rates dramatically.

X-Linked Disorders
PGT offers families the ability to avoid transmission of disorders linked to X chromosomes, including hemophilia and Duchenne muscular dystrophy.

Structural Chromosomal Abnormalities
Chromosomal rearrangements can lead to implantation failures or congenital disorders. PGT-SR (structural rearrangement testing) allows for identification of such anomalies.

Single Gene Disorders
PGT-M (monogenic testing) is essential for families with histories of genetic diseases such as cystic fibrosis, Tay-Sachs, and Huntington's disease.

Gender Identification
While ethically regulated in many regions, gender identification remains important for medical reasons, including avoiding sex-linked disorders.

HLA Typing for Stem Cell Transplants
PGT enables the selection of embryos with compatible HLA types to serve as potential stem cell donors for affected siblings, offering life-saving therapeutic options.

By Distribution Channel

PGT services are delivered through various channels, each contributing significantly to market expansion.

Hospitals
Hospitals with advanced reproductive facilities are integrating PGT as a standard component of fertility care.

Fertility Clinics
Representing the largest share of market demand, fertility clinics conduct the vast majority of IVF procedures and maintain partnerships with genetic laboratories for embryo testing.

Diagnostic Laboratories
Specialized genetic labs provide high-throughput sequencing and analysis services, supporting clinics worldwide.

Academic & Research Institutions
Research institutions play a vital role in developing new PGT technologies and improving screening accuracy.

Others
This category includes standalone IVF centers and private healthcare providers that offer specialized reproductive services.

Know More: https://www.persistencemarketresearch.com/market-research/preimplantation-genetic-testing-market.asp

Regional Outlook

North America

North America continues to dominate the global PGT market, driven by advanced healthcare infrastructure, high adoption of IVF technologies, favorable reimbursement policies, and strong presence of leading biotechnology companies. The United States remains a major contributor due to rising incidences of genetic disorders and a growing trend toward family planning at older ages.

Europe

Europe remains a strong market owing to robust healthcare systems, progressive reproductive rights policies, and widespread acceptance of genetic screening. Countries such as the UK, Germany, and France have well-established IVF centers with advanced genomic capabilities.

East Asia

East Asia is experiencing rapid market growth driven by expanding access to fertility treatments, declining birth rates, and increasing government support for reproductive health services. China, Japan, and South Korea are leading the region’s adoption of PGT technologies.

South Asia and Oceania

With growing populations and an increasing burden of infertility, countries such as India and Australia are witnessing rising demand for IVF and genetic testing. Improvements in diagnostic infrastructure and greater awareness of genetic health are boosting market penetration.

Latin America

Latin America is emerging as a promising market, propelled by expanding medical tourism for fertility treatments, particularly in Brazil, Mexico, and Argentina. Lower procedural costs compared to North America are attracting international patients seeking PGT services.

Middle East and Africa

The Middle East shows strong potential due to rising fertility clinic networks and growing emphasis on genetic health within affluent populations. Africa, though still in nascent stages, is gradually adopting IVF technologies, laying groundwork for future PGT growth.

Competitive Landscape

The PGT market is characterized by the strong presence of global biotechnology leaders and innovative genomics companies. Key players include Thermo Fisher Scientific, COOPER SURGICAL, Illumina, Abbott, Agilent Technologies, Medicover Genetics, Revvity, Takara Bio, Genea BIOMEDX, SeraCare Life Sciences, and Shiva Scientific Company, among others. These companies are heavily investing in next-generation sequencing platforms, advanced consumables, and AI-powered embryo analysis tools.

Collaborations between fertility clinics and genetic labs are becoming increasingly common to deliver integrated testing solutions. Companies are also focusing on expanding their global footprint, developing cost-effective products, and enhancing accuracy through sophisticated bioinformatics pipelines.

Market Drivers, Challenges, and Future Opportunities

Key Growth Drivers

• Increasing global infertility rates

• Rising awareness of genetic diseases

• Technological advancements in NGS and AI

• Expanding access to IVF services

• Favorable regulatory frameworks in key markets

Major Challenges

• High cost of PGT procedures

• Ethical and legal concerns surrounding embryo testing

• Limited awareness in developing regions

• Need for skilled professionals and advanced lab infrastructure

Future Opportunities

Emerging markets, improved affordability through technological innovation, and the integration of AI and machine learning for embryo selection are set to create lucrative opportunities. Expanding applications such as polygenic risk scoring, non-invasive embryo testing, and personalized reproductive care will further shape the market’s evolution through 2032.

Conclusion

The global preimplantation genetic testing market is entering a period of sustained growth, supported by scientific advancements, evolving reproductive health needs, and increasing acceptance of genetic screening as a vital tool for ensuring healthy pregnancies. With its market value expected to nearly double by 2032, PGT will continue to play a transformative role in modern fertility care, offering hope to millions of families worldwide seeking safe and successful paths to parenthood.